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Abstract
Background: The exact relationship between hormonal activity and prostate cancer(PCa) has not
yet been clearly defined. One of the key hormones associated with PCa is testosterone(T).
However, both in vitro and in vivo studies have shown that under some conditions T is capable of
either promoting PCa growth or death. This article proposes a theory which resolves this apparent
paradox.
Model: The Estradiol-Dihydrotestosterone(E-D) model introduced in this paper proposes that
17β -estradiol(E2) is essential for initiating the growth of PCa cells through the formation of
telomeres. It also proposes that T is responsible for increasing the expression of proteins which
cause apoptosis, or programmed cell death, and that 5α -dihydrotestosterone(DHT) is essential for
preventing this. In addition, it is known that some T is converted to both E2 and DHT, which means
that depending on the conditions, T is capable of either promoting the growth of or the killing of
PCa.
Background
There are currently two models for prostate cancer(PCa)
which are diametrically opposed to each other. One
model[1] proposes that high levels of androgens are
responsible for PCa. This model is unable to explain the
fact that androgen levels drop with age while the inci-
dence of PCa increases. The other model[2] proposes that
high levels of androgen should be effective in the preven-
tion and treatment of PCa. While this model is consistent
with the relationship of PCa to age, it does not explain
experiments in which increased levels of androgen have
been shown to increase the incidence of PCa, such as the
correlation of increased incidence of PCa with higher lev-
els of free testosterone(T)[3].
Model
Model description
The Estradiol-Dihydrotestosterone(E-D) model of PCa,
proposed in this paper, hypothesizes that 17β -estra-
diol(E2) is essential for turning on telomerase in PCa,
resulting in telomere formation. It is hypothesized that it
does this by binding to a heterodimer composed of one
estrogen receptor-α (ER-α ) and one estrogen receptor-β
(ER-β ). This model proposes that telomere formation is
an essential step for initial PCa growth. It also hypothe-
sizes that 5α -dihydrotestosterone (DHT) is essential for
initial PCa growth by binding to the intracellular andro-
gen receptor(iAR), which results in the cell being pro-
tected from the apoptosis caused by androgens binding to
the membrane xandrogen receptor(mAR). Finally, it pro-
poses that T binds to mAR and upregulates proteins that
promote apoptosis, such as U19, ALP1, and Fas.
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All of the above hormones also have other interactions
which affect PCa. The E-D model proposes that when T
binds to mAR, it upregulates bcl-2, a protein that protects
against apoptosis, whereas when DHT binds to iAR, bcl-2
is downregulated. It is hypothesized that the expression of
bcl-2 increases when E2 binds to ER-α  and decreases when
E2 binds to ER-β . It is known that T is converted to E2 by
the enzyme aromatase(Aro) and is converted to DHT by
the enzyme 5-α  reductase type II(5AR2).
Supporting evidence
It has been observed that mice never get PCa if they have
a genetic mutation resulting in a lack of ER-α [4] or Aro[5].
These findings are consistent with the E-D model, which
would also predict that mice with a genetic mutation
resulting in a lack of ER-β  would never get PCa.
Aro activity was not observed[5] in normal epithelial
prostate cells, but was observed in all of the PCa cell lines
tested. E2 has been shown[6] to turn on telomerase activ-
ity, with both ER-α  and ER-β  being involved, in human
epithelial cells as well as in tissue cultures of PCa. Some
researchers believe that telomerase activity is an essential
step for all types of cancer[7]. These findings are consist-
ent with the prediction of the E-D model that E2 is essen-
tial for the initiation of PCa growth by bringing about
telomere formation.
Implantation of PCa xenografts into intact and ovariect-
omized female mice showed that E2 inhibited the growth
of 5 out of the 6 xenografts tested[8]. The authors con-
cluded that "the observed inhibition of PCa growth may
be attributable to direct effects of estrogens via ER-β ".
Mice with a genetic mutation lacking ER-β [9] have an
overexpression of bcl-2 in their ventral prostate. E2 has
been shown[10] to increase the production of bcl-2 in
MCF-7, an ER-α  positive cell line of breast cancer. This
increase is negated by the addition of 4-hydroxyta-
moxifen(OHT). It is known[11] that OHT acts as an
antagonist to ER-α . All of this is consistent with the
hypotheses of the E-D model that E2 increases the produc-
tion of bcl-2 when binding to ER-α  and decreases it when
binding to ER-β .
It has been shown[12] that T binds to mAR to produce
apoptosis by upregulating the protein Fas. In the PCa cell
line DU145 which lacks iAR, T or DHT alone was suffi-
cient to induce apoptosis. However, in LNCaP, a hormone
sensitive PCa cell line which has a functional iAR, T pro-
motes cell growth unless it was given in the form of T-BSA,
which does not enter the cell nor bind to the iAR, in which
case apoptosis was also induced. This shows that the bind-
ing of androgens to iAR can counteract the apoptosis oth-
erwise induced by the binding of androgens to mAR, as
proposed in the E-D model.
It has been shown[13] that T upregulates a protein, U19,
which induces apoptosis in PCa. This apoptosis was
inhibited by mibolerone, a synthetic androgen, binding
to the iAR. Another protein, ALP1, that was upregulated
by T, was also found[14] to induce apoptosis. These find-
ings are all consistent with the E-D model.
When finasteride(F), an inhibitor of 5AR2, is added to
LNCaP, it inhibits growth in a dose-dependent man-
ner[15]. Apoptosis resulted at the highest dose tested. This
indicates that T binding to iAR is not able to completely
prevent the apoptosis induced by T binding to mAR,
whereas DHT is. This can be represented symbolically as
T:mAR >>> T:iAR in the presence of F and DHT:iAR >>>
T:mAR in the absence of F. This is consistent with the
hypothesis of the E-D model that DHT is essential for ini-
tial PCa growth because it protects the PCa from mAR
induced apoptosis.
It is known[1] that men with a genetic mutation that pro-
duces non-functional 5AR2 do not get PCa. Since 5AR2 is
found within the prostate cells and converts T to DHT, the
result is very little DHT in the prostate. This finding is con-
sistent with the hypothesis that in the absence of DHT, T
binding to iAR in PCa is not able to prevent the apoptosis
caused by T binding to mAR.
It has been shown[16,17] that in a small percentage of
men with castrate metastatic PCa, enormous improve-
ment in symptoms occurred following the administration
of T. One possible explanation for this is that the PCa in
those individuals might have lacked a functional iAR, but
retained a functional mAR. The fact that T alone is some-
times capable of causing apoptosis in vivo is consistent
with the E-D model.
When pyrrolidinedithiocarbamate(PDTC), a strong anti-
oxidant, is added to LNCaP, it induces apoptosis[18]. It
was shown that when 10-12 M T was added to LNCaP, it
increased the growth rate, but when it was added in addi-
tion to PDTC, the amount of apoptosis was greater than
that induced by PDTC alone. This again shows that T is
capable of inducing apoptosis under the proper circum-
stances.
T has been shown[12] to increase bcl-2 production when
it binds in the form of T-BSA to the mAR of LNCaP. T-BSA
was shown not to bind to iAR. DHT has been shown[19]
to decrease bcl-2 production when it binds to the iAR of
LNCaP-FGC. This decrease was inhibited by the addition
of bicalutamide, an antiandrogen which interferes with
the binding of DHT to iAR. This is consistent with mAR
being involved in the upregulation of bcl-2 and iAR being
involved with the down-regulation of bcl-2, as proposed
in the E-D model.Theoretical Biology and Medical Modelling 2005, 2:10 http://www.tbiomed.com/content/2/1/10
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Discussion
The E-D model, presented in this paper, does not explain
how genetic mutations occur that cause PCa, but does
explain which factors are essential for PCa to grow. The
crucial factors for initial PCa growth are telomere forma-
tion and apoptosis avoidance. Since E2 produces telomere
formation[6], in the absence of high levels of exogenous
E2, Aro activity would initially be needed to supply PCa
with large amounts of E2. The binding of normal amounts
of DHT to iAR is sufficient for PCa to initially avoid apop-
tosis. As mutations develop that interfere with the process
of apoptosis, DHT binding to iAR may no longer be nec-
essary.
The evidence is overwhelming that T is capable of induc-
ing apoptosis in PCa. The in vitro and in vivo studies are
unambiguous in this regard. The study with PDTC[18]
raises interesting questions that can only be answered
with further experimentation. There are three possible
explanations as to why T increased the apoptosis caused
by PDTC. Either PDTC interfered with the binding of
androgens to iAR, or PDTC inhibited 5AR2, or PDTC may
have enhanced the ability of T to cause apoptosis when
binding to mAR. If the latter is true, it would have impor-
tant implications in preventing and treating PCa, espe-
cially if other anti-oxidants should also be found to
exhibit this same sort of enhancement.
Assuming that the genetic studies with mice are applicable
to humans, then it is clear that E2 is essential in order for
PCa to occur. The evidence is only circumstantial that E2
is binding to a heterodimer of ER-α  and ER-β . If a dimer
were not involved, then one would expect that small
amounts of E2 would be sufficient to induce telomerase
activity. The heterodimer is consistent with the observa-
tion that both ER-α  and ER-β  are involved in telomere for-
mation[6]. The hypothesis that telomere formation is
essential for all cancers to occur[7] is not a proven fact, but
it gives a plausible explanation as to why E2 is initially
essential for PCa.
The genetic study in mice[9] makes it clear that ER-β  acts
to inhibit bcl-2 production. The evidence that ER-α
increases bcl-2 production is more circumstantial. It is
known[20] that ER-α  and ER-β  tend to counteract each
other. The increase in bcl-2 in the breast cancer line
exposed to E2[10] is consistent with ER-α  being responsi-
ble for increasing bcl-2. However, this assumes that the
effect remains the same when the same hormone binds to
the same hormone receptors in breast and prostate can-
cers. This is an intriguing concept, and would imply that
the different overall effects that hormones have on these
two cancers could be explained by the different amounts
of each hormone receptor present in them. More research
is needed to learn if breast cancer also possesses mAR and
iAR acting in opposition to each other, as they do in PCa.
High dosages of E2 have been used in the treatment of
PCa. Transdermal patches of E2 have been shown to pro-
duce castrate levels of T within 3 weeks[21]. It is known
that castrate levels of T result in apoptosis of most PCa
cells, with calcium overload being one of the causes[22].
Calreticulin protects prostate cells from apoptosis due to
calcium overload by enhancing the calcium buffering
capacity, but castrate levels of T dramatically downregu-
late calreticulin. More research is needed to determine
whether calreticulin is upregulated by mAR, iAR, or both.
The fact that Aro activity was found in PCa cell lines, but
not in normal prostate cell lines[5], does not mean that it
is present in all PCa. Even if E2 is necessary for telomere
formation, once telomeres of sufficient length are formed,
Aro activity may no longer be necessary. It is interesting to
note that the level of Aro activity observed in the PCa cell
lines falls within the range observed in breast cancer cell
lines[5].
The assumption of the E-D model that when DHT binds
to iAR it counters the effect of apoptosis induced when T
binds to mAR is supported by the study[15] that showed
that increases in F decreased the growth of LNCaP in a
dose-dependent manner, with the highest dose causing
apoptosis. If the behaviour in vivo is the same as this in
vitro result, then it explains why men with defective 5AR2
would not get PCa[1].
There are many questions still to be answered about PCa.
Do the progesterone(P) receptor isomers, PRA and PRB,
affect bcl-2 production? What is the dose effect of T, DHT,
E2, and P on each of their corresponding receptors? For
the hormone receptor pairs, to what extent does each
receptor work against the other?
Another important issue is how mAR is involved in the
apoptosis of aged normal prostate cells. The fact[12] that
T is capable of causing apoptosis in PCa which lacks iAR
indicates that the increased amount of bcl-2 produced by
mAR is not sufficient to counteract the apoptotic proteins
produced by mAR. The makes it likely that the production
of bcl-2 by mAR represents a damping factor designed to
protect normal prostate cells from inappropriate apopto-
sis that might otherwise be caused by local fluctuations in
serum T levels. If it turns out that calreticulin[22] is upreg-
ulated by mAR, then the absence of mAR should lead to
apoptosis through calcium overload. As normal prostate
cells age, if they start to lose functionality of mAR, iAR, or
both, then the probability of apoptosis occurring should
increase as the amount of functional AR decreases.Publish with BioMed Central    and   every 
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It is beyond the scope of this paper to develop detailed
descriptions of treatments for preventing or treating PCa.
However, it is clear that treatments that maximize the pro-
apoptotic properties of mAR, minimize the anti-apoptotic
properties of iAR, and minimize overall bcl-2 production
should be of therapeutic value. An example of this would
be a combination of T, F, and methyl-piperidino-pyra-
zole(MPP) along with avoiding foods known to have
components that selectively bind to ER-β . MPP has been
shown[23] to be an antagonist of ER-α  but not of ER-β .
Conclusion
The E-D model presented here is consistent with known
experimental data. Further research is needed to more
completely verify and expand its hypotheses. It explains
how T can promote either PCa growth or apoptosis and
why E2 and DHT are essential for initial PCa growth.
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